FIG. 1A

CAR construct (no tag)




FIG. 1B

CAR construct (N-terminal tag)




FIG. 1C

CAR construct (Linker tag)




FIG. 1D

CAR construct (Hinge tag)




FIG. 1E

TCR construct (no tag)




FIG. 1F

TCR construct (N-terminal TCRbeta Variable tag)




FIG. 1G

TCR construct (TCRbeta Variable-tag-TCRbeta Constant)




FIG. 1H

TCR construct (Linker tag)




FIG. 1I

TCR construct (TCRalpha Variable-tag-TCRalpha Constant)




FIG. 1J

TCR construct (no tag)




FIG. 1K

TCR construct (N-terminal TCRalpha Variable tag)




FIG. 1L

TCR construct (TCRalpha Variable-tag-TCRalpha Constant)




FIG. 1M

TCR construct (Linker tag)




FIG. 1N

TCR construct (TCRbeta Variable-tag-TCRbeta Constant)




FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D





+ tarlatamab
*
Percent CD69 positive
0
10
20
30
ML73
ML141 (Tarlatamab)

FIG. 3B



ns
****
Percent CAR positive
0
10
20
30
40
ML73 initial
ML73 + tarlatamab
ML141 initial
ML141 + tarlatamab

FIG. 3A

FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8A



Percent CAR positive
0
10
20
30
40
50
Untransduced
ML73
ML122 (TROP2 tag)

FIG. 8B



Percent Sacituzumab positive
0
20
40
60
80
100
AU565 (control)
ML73
ML122 (TROP2 tag)

FIG. 9A



T cells expressing CAR with moga tag
UTD
GFP+
0.079%
GFP+
83.5%
FSC-A :: FSC-A
BL1-A :: GFP-A
1.0M
800K
600K
400K
200K
0
10^4
10^5

FIG. 9B



Primary T Cells: 24 h ADCC Assay
2:1
5:1
10:1
% GFP Positive
(normalized to isotype)
140
120
100
80
60
40
20
0
100
63
46
64
100
43
41
39
100
33
28
29
0.1ug/mL isotype
1ug/mL mogp
10ug/mL mogp
0.1ug/mL isotype
1ug/mL mogp
10ug/mL mogp
0.1ug/mL isotype
1ug/mL mogp
10ug/mL mogp

FIG. 9C



Peripheral Blood
Cell Counts
UTD
Untreated
Day 7 hOpa Treatment
Day 14 hOpa Treatment

FIG. 9D



hCD45 Absolute Counts in Tissue
Blood (cells/ul blood)
BM (cells/femur)
Spleen (cells/spleen)
Cell Counts
UTD
Untreated
Single hOpa Dose
Repeat hOpa Doses

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11I




FIG. 11H




FIG. 11G




FIG. 11F




FIG. 11E




FIG. 11J




FIG. 11K




FIG. 11L




FIG. 11M




FIG. 11N




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 12H




FIG. 12I

